Updated Announcement—AAPS and FDA Agreement to Build Quantitative Alzheimer’s Disease Model
Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 2
Abstract
Authors and Affiliations
Peter Inchauteguiz
Keywords
Related Articles
- EP ID EP681567
- DOI 10.1208/s12248-008-9051-6
- Views 79
- Downloads 0
Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling
Precision medicine promises to improve both the efficacy and safety of therapeutic products by better informing why some patients respond well to a drug, and some experience adverse reactions, while others do not. Pharma...
Understanding the Effect of API Properties on Bioavailability Through Absorption Modeling
This article inadvertently failed to include two of the theme issue guest editors. The complete listing of the guest editors is shown in this erratum.
Large Molecule Specific Assay Operation: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team
The L2 Global Harmonization Team on large molecule specific assay operation for protein bioanalysis in support of pharmacokinetics focused on the following topics: setting up a balanced validation design, specificity tes...
Ligand Binding Assays in the 21st Century Laboratory: Platforms
A high level of precision is required to generate reproducible bioanalytical results for the measurement of drug, biomarker concentrations, and detection of immunogenic responses. Precision for LBAs analytical assays use...
Investigation of the Performance of the Disintegration Test for Dietary Supplements
The aim of this study was to investigate how beaker size, basket assembly, use of disk, and immersion medium impact the disintegration time of dietary supplements. The disintegration times were determined for five tablet...